Pasar al contenido principal

ALTERACIONES DEL CONTROL EPIGENETICO DEL DESARROLLO EN ENFERMEDADES RARAS Y LEUCEMIA

PID2021-122787OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NSD2 as a Promising Target in Hematological Disorders

  • Azagra, Alba
  • Cobaleda, César
Alterations of the epigenetic machinery are critically involved in cancer development and maintenance; therefore, the proteins in charge of the generation of epigenetic modifications are being actively studied as potential targets for anticancer therapies. A very important and widespread epigenetic mark is the dimethylation of Histone 3 in Lysine 36 (H3K36me2). Until recently, it was considered as merely an intermediate towards the generation of the trimethylated form, but recent data support a more specific role in many aspects of genome regulation. H3K36 dimethylation is mainly carried out by proteins of the Nuclear SET Domain (NSD) family, among which NSD2 is one of the most relevant members with a key role in normal hematopoietic development. Consequently, NSD2 is frequently altered in several types of tumors—especially in hematological malignancies. Herein, we discuss the role of NSD2 in these pathological processes, and we review the most recent findings in the development of new compounds aimed against the oncogenic forms of this novel anticancer candidate., Research at C.C.’s laboratory was partially supported by the Ministerio de Ciencia e Innovación/AEI/FEDER (PID2021-122787OB-I00), by the Fundación Científica de la Asociación Española contra el Cáncer (PRYCO211305SANC), and by a Research Contract with the Fundación Síndrome de Wolf–Hirschhorn o 4p-. Institutional grants from the Fundación Ramón Areces and Banco de Santander to the CBMSO are also acknowledged. The C.C. laboratory was member of the EU COST Action LEGEND (CA16223).